Transforming Clinical and Translational Research and Education at Rockefeller

改变洛克菲勒的临床和转化研究与教育

• 批准号: 7495993
• 负责人: Barry Coller
• 金额: $ 91.8万
• 依托单位: ROCKEFELLER UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7495993
• 关键词: Adopted; Advocate; Biometry; Clinical; Clinical Protocols; Clinical Research; Clinical and Translational Science Awards; Communities; Complement; Dendritic Cell Therapy; Development; Discipline; Doctor of Philosophy; Education; Faculty; Functional disorder; Genetic; Genomics; Goals; HIV; Hepatitis C; Home environment; Human; Immune response; Indium; Industry; Malignant Neoplasms; Medical; Metabolic; Methodology; NCI Scholars Program; Nursing Research; Participant; Pharmacy facility; Phenotype; Preventive; Range; Research; Research Infrastructure; Research Personnel; Research Subjects; Resources; Safety; Site; Standards of Weights and Measures; Structure; Therapeutic; Translational Research; U-Series Cooperative Agreements; United States National Institutes of Health; Universities; University Hospitals; Vaccine Therapy; biomedical informatics; human subject; innovation; member; novel; novel diagnostics; programs; tool; vaccine development

The Rockefeller University Hospital, a GGRC awardee since 1963, has been the continuous "home" for clinical and translational science at Rockefeller since 1910. It has been the site of numerous landmark scientific and clinical contributions, and many of its trainees have gone on to become academic leaders. With the new resources available under a Clinical and Translational Science Award (CTSA), a core faculty of. distinguished investigators, whose research spans the basic-translational spectrum and encompasses a broad range of scientific and medical disciplines, will integrate and expand their scientific and educational programs in a new Rockefeller University Center for Clinical and Translational Science. The new Center will transform clinical and translational research by encouraging new studies, and by enhancing and centralizing the support structures required to conduct studies with scientific rigor and an absolute commitment to protection of human subjects and participant safety. The key elements in the transformation will be: 1) A new governance structure reflecting the NIH cooperative agreement (U54) "assistance" mechanism, 2) Creation of a new K-12 Clinical Research Scholars Program offering Masters and PhD level degrees to complement the current Clinical Scholars Program, 3) Infrastructure enhancements to facilitate the development and conduct of clinical protocols under the principle of Good Clinical Practice (GCP), including biomedical informatics, biostatistics, bionutrition, research nursing, research pharmacy, participant recruitment and community engagement, and regulatory support and oversight from the clinical research (research subject advocate) support office, 4) Development of innovative and novel core methodologies related to dendritic cell therapy; vaccine development for HIV, hepatitis C, and malignancies; genetics/genomics; assessing the immune response; and metabolic phenotyping. The Center will continue Rockefeller's tradition of focusing on the interface between scientific discovery, human pathophysiology, and novel diagnostic, preventive and therapeutic strategies. It will partner with industry, when mutually beneficial, to achieve these goals. The Center will also be an active member of the National CTSA Consortium, offering the Consortium novel ideas and tools for conducting and evaluating clinical and translational research. It will also eagerly adopt the best practices identified by the Consortium and adhere to the standards set by the Consortium.

洛克菲勒大学医院自1963年以来一直是GGRC的获奖者， 临床和转化科学在洛克菲勒自1910年以来。它是众多地标的所在地 科学和临床的贡献，它的许多学员已经成为学术领袖。与 根据临床和转化科学奖（CTSA），一个核心的教师提供的新资源。 杰出的研究人员，其研究跨越基本的翻译谱，包括 广泛的科学和医学学科，将整合和扩大其科学和教育 洛克菲勒大学临床和转化科学中心的一个新项目。新中心将 通过鼓励新的研究，以及通过加强和集中 进行科学严谨的研究所需的支持结构，并绝对致力于 保护人类受试者和参与者安全。转型的关键要素将是：1）新的 反映NIH合作协议（U 54）“援助”机制的治理结构，2）创建 新的K-12临床研究学者计划提供硕士和博士学位，以补充 目前的临床学者计划，3）基础设施的改进，以促进发展和 根据药物临床试验质量管理规范（GCP）原则开展临床方案，包括生物医学 信息学、生物统计学、生物营养学、研究护理学、研究药学、参与者招募和 社区参与，以及来自临床研究（研究主题）的监管支持和监督 倡导者）支持办公室，4）开发与树突状细胞相关的创新和新颖的核心方法 治疗;艾滋病毒、丙型肝炎和恶性肿瘤的疫苗开发;遗传学/基因组学;评估 免疫应答和代谢表型。该中心将延续洛克菲勒的传统， 科学发现，人类病理生理学和新的诊断，预防和治疗之间的接口 治疗策略它将在互利的情况下与工业界合作，以实现这些目标。的 中心还将成为国家CTSA联盟的积极成员，为该联盟提供开展和评估临床和转化研究的新想法和工具。它还将急切地采用最好的 联合体确定的做法，并遵守联合体制定的标准。